[血液生物标志物为阿尔茨海默病中的大脑病理生理学打开了一个窗口]
1överläkare , kliniska neurokemiska laboratoriet, Sahlgrenska universitetssjukhuset, Mölndal; Göteborgs universitet.
Lakartidningen
|May 31, 2024
概括
新的血液测试可以检测阿尔茨海默病 (AD) 病理. 化 (P-tau217) 和来自大脑的 (BD-tau) 在诊断AD神经退行症和指导早期认知症状管理方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 临床诊断 临床诊断 临床诊断
背景情况:
- 超敏感的分析方法可以精确量化血液中的脑蛋白.
- 阿尔茨海默病 (AD) 诊断面临着当前生物标志物 (如Aβ42/40比率) 的挑战,因为它们与正常衰老重叠.
- 准确的基于血液的生物标志物是早期阿尔茨海默病检测和管理所需的.
研究的目的:
- 评估各种基于血液的蛋白质生物标志物的潜力,以确定阿尔茨海默病 (AD) 病理生理学.
- 评估这些生物标志物在早期认知障碍诊断和临床管理中的有用性.
- 为了确定预测或排除大脑粉样化症的两步模型的准确性.
主要方法:
- 血粉样蛋白β (Aβ42 / 40比率),酸化 (P-tau217,T-tau,BD-tau),神经丝光 (NFL) 和状纤维酸性蛋白质 (GFAP) 的量化.
- 血液生物标志物水平与阿尔茨海默病诊断和其他神经退行性疾病的比较.
- 评估早期症状阶段的生物标志物性能和与脑成像 (PET) 的相关性.
主要成果:
- 血P-tau217在早期症状性AD显著增加,在其他神经退行性疾病中正常.
- 血Aβ42/40比率显示与大脑粉样性粉症一致,但与正常老年人有显著的重叠.
- 在AD型神经退行症中,BD-tau显得有前途,而NFL和GFAP则在各种大脑疾病中分别表明轴突损伤和天体细胞激活.
- 总tau (T-tau) 更多地表明急性神经元损伤,而不是AD.
结论:
- 血液测试,特别是P-tau217和潜在的BD-tau,显示出在早期认知症状患者中识别AD病理生理学的重大前景.
- 这些生物标志物可以帮助初级保健机构进行初步患者评估,指导管理和专家转诊.
- 一个两步生物标志物模型可以在预测或排除阿尔茨海默氏症类型大脑粉样化症方面实现高准确性.
相关概念视频
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
01:30Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
00:49The Blood-brain Barrier
47.2K
Overview
47.2K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
77
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
77